Trusted Resources: Evidence & Education
Scientific literature and patient education texts
A Validated Tool Can Predict Risk of Developing Thyroid Eye Disease During Antithyroid Drug Treatment of Graves’ Disease
source: Clinical Thyroidology
year: 2018
summary/abstract:Over-activity of the thyroid gland, called hyperthyroidism, can sometimes be caused by a flaw in a person’s immune system (the body’s natural defense system against infection). This problem is a type of autoimmune disorder called Graves’ disease. In addition to thyroid gland over-activity, Graves’ disease causes eye problems in some people, including eye bulging, loss of color vision, double vision, eye pain and dry eyes.
Not everyone diagnosed with Graves’ disease will develop eye problems. Identifying people diagnosed with Graves’ disease who do develop eye disease is important, however, because early treatment may make these eye problems less severe. The goal of this study is to identify which people diagnosed with Graves’ disease will eventually have eye problems. Such people could then be treated for these eye problems before these problems become severe, and possibly irreversible.
read more
myBinderRelated Content
-
Massachusetts Eye and Ear – Center for Thyroid Eye Disease and Orbital SurgeryThe multidisciplinary Center for Thyroid...
-
Teprotumumab Significantly Improves Proptosis in Thyroid eye DiseasePatients with thyroid eye disease treate...
-
Thyrotropin Receptor Antibody Levels at Diagnosis and After Thionamide Course Predict Graves’ Disease RelapseBackground: Thionamides are associated ...
-
Medication for Graves’ Disease in ChildrenDoctors at Hassenfeld Children’s Hospi...
-
Thyroid Eye Disease Drug Meets Primary Endpoint for Proptosis ReductionTop-line results from the OPTIC trial sh...
-
Advances in Treatment of Active, Moderate-To-Severe Graves’ OphthalmopathyGraves' ophthalmopathy is defined as aut...
-
New Data from Phase 3 Teprotumumab Trial Shows Dramatic Reduction in Proptosis, or Eye Bulging, the Main Cause of Mo...Horizon Pharma plc today announced that ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Facebook
Google